• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

Exploring Changes in Atopic Dermatitis Severity Across the Pregnancy Journey

Author(s):

Elizabeth Kiracofe, MD, FAAD,Jenny Murase, MD, FAAD

Jenny Murase, MD, describes how rising estrogen levels cause a shift in immune response from Th1 to Th2, causing potential atopic dermatitis exacerbations for patients who are pregnant.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Limited Evidence Supporting the Efficacy of Antifungals for Atopic Dermatitis
January 17th 2025

Limited Evidence Supporting the Efficacy of Antifungals for Atopic Dermatitis

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Nutrition, Obesity, and Anxiety Can Impact the Severity of Seborrheic Dermatitis
January 15th 2025

Nutrition, Obesity, and Anxiety Can Impact the Severity of Seborrheic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin
January 10th 2025

Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin

Ruxolitinib Cream Shows Strong Efficacy in Max-Use Pediatric Trial
January 9th 2025

Ruxolitinib Cream Shows Strong Efficacy in Max-Use Pediatric Trial

© 2025 MJH Life Sciences

All rights reserved.